Essa Pharma Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Essa Pharma Inc 's ROA in the third quarter of 2025?
Essa Pharma Inc recorded a cumulative net loss of $-25 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -21.2%.

However, within the Healthcare sector 375 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 3605, from total ROA ranking in the second quarter of 2025 at 3695.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) III. Quarter	(Mar 31 2025) II. Quarter	(Dec 31 2024) I. Quarter	(Sep 30 2024) IV. Quarter	(Jun 30 2024) III. Quarter
Y / Y Total Assets Change	25.16 %	23.26 %	152.22 %	93.37 %	121.14 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-25	-28	-31	-29	-28
Return On Assets (TTM)	-21.2 %	-25.09 %	-28.77 %	-30.44 %	-36.88 %
EPIX's Total Ranking	# 3605	# 3695	# 4311	# 3728	# 3710
Total Assets (TTM) in million	111	115	95	155	88
Seq. Total Assets Change	-4.26 %	21.1 %	-38.66 %	75.99 %	-5.71 %
Seq. Net Income Change	-	-	-	-	-

EPIX's 5 Years Annual ROA >> Back to EPIX Management Effectiveness >> Compare EPIX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 137
Sector	# 376
Overall	# 3557

Return On Assets Statistics
High	Average	Low
-16.96 %	-26.76 %	-72.61 %
(Jun 30 2023)		(Sep 30 2018)

Financial Statements
Essa Pharma Inc 's Assets	$ 111 million	EPIX's Balance sheet
Essa Pharma Inc 's Income	$ -4 million	Quarterly EPIX's Income Statement
EPIX's Income by Division		See EPIX's Income by Division

Annual Return On Assets	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021	(Sep 30 2020) FY 2020
Y / Y Total Assets Change	93.37 %	-19.18 %	-57.05 %	123.46 %	-19.28 %
Total Assets in million	155	80	99	231	104
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-29	-27	-35	-37	-23
Annual Return On Assets	-18.37 %	-33.08 %	-35.31 %	-15.9 %	-22.64 %

EPIX's 5 Years Annual ROA >> Back to EPIX Management Effectiveness >> Compare EPIX ROA to its Competitors

More Return On Assets Ratios
EPIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EPIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EPIX's Competitors
Subscribers only: Roa for Essa Pharma Inc 's Suppliers
Subscribers only: Return On Assets for EPIX's Customers

You may also want to know
EPIX's Roi	EPIX's Inventory Turnover Ratio	EPIX's Growth Rates	EPIX's Dividend Comparisons
	EPIX's Profitability Ratios	EPIX's Asset Turnover Ratio	EPIX's Dividend Growth
EPIX's Roe	EPIX's Valuation Ratios	EPIX's Financial Strength Ratios	EPIX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:33:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.